In chronic lymphocytic leukemia (CLL), covalent Bruton tyrosine kinase (BTK) inhibitors exert their activity by binding to cysteine residue 481 of the BTK protein [245]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.